Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 4 1

Status

Recruiting 8Completed 5Unknown 4Not yet recruiting 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 299Solid Tumors 184Advanced Solid Tumors 168Solid Tumor 152Mesothelioma, Malignant 152Mesothelioma 121Advanced Solid Tumor 97Carcinoma, Non-Small-Cell Lung 50Retinoblastoma 48Lung Neoplasms 37Solid Tumor, Adult 36Sarcoma 31Ovarian Neoplasms 29Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Small Cell Lung Carcinoma 25Melanoma 25Pancreatic Neoplasms 24Breast Neoplasms 24Unspecified Childhood Solid Tumor, Protocol Specific 23Esophageal Neoplasms 21Uterine Cervical Neoplasms 20Solid Tumours 20Solitary Fibrous Tumor, Pleural 19Osteosarcoma 19Colorectal Neoplasms 17Neuroblastoma 16Head and Neck Neoplasms 16Carcinoma, Hepatocellular 16

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1Topotecan 1SAR125844 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Malignant Solid Tumors × Other solid neoplasm × Clear all
NCT05930457 2023-12-26

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

The First Affiliated Hospital of Guangzhou Medical University

Phase 1 Completed
15 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT05814835 2023-12-20

First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Chinese PLA General Hospital

Phase 1 Completed
14 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT02805166 2016-06-17

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 4 Completed
420 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT01391533 2016-04-13

SARMET

Sanofi

Phase 1 Completed
72 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT00516438 2010-12-08

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

AstraZeneca

Phase 1 Completed
48 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡